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Control of complement activation in membranous and mem-
branoproliferative glomerulonephritis. Renal biopsy specimens
from 22 membranous (MGN) and 19 membranoproliferative gb-
merubonephritis (MPGN) patients were examined for the pres-
ence of the three regulators of the complement system; Cl inhib-
itor (Cl-INH), C3b inactivator (C3b-INA), and /3 lH. The serum
concentrations of these proteins, at the time of biopsy, were also
measured. To study the modulation of complement activation by
these three control proteins in MGN and MPGN, we examined
the relationship between each control protein and the protein
whose activity it regulates, in four ways: (a) the concordance
between the presence of the control proteins and the components
regulated was studied, (b) the correlations in intensity of deposi-
tion of the control and complement proteins were measured, (c)
the patterns of distribution of the proteins within the glomeruli
were compared, and (d) the serum levels of control proteins and
components regulated were examined. C1-INH (23 of 35
biopsies) and /3IH (34 of 36 biopsies) were frequently deposited
in both disease groups. C3b-INA was found only rarely in
MPGN (4 of 19 biopsies). This is probably because the former
two proteins modulate complement activation stoichiometri-
cabby, whereas C3b-INA acts enzymatically. A relationship was
demonstrated between Ci-INH and CIs and between /31H and
C3 in both groups, but no such relationship was found between
C3bINA and C3. Conclusion. There is no generalized deficiency
in modulation of complement activation in MGN or MPGN.
Contrôle de I'activation du complement dans les glomérulo-
néphrites extramembraneuses et membranoprolifératives. Les
biopsies rénabes de 22 glomerulonéphrites extramembraneuses
(MGN) et de 19 gbomérulonéphntes membranoprolifératives
(MPGN) ont été étudiées pour la presence de trois régulateurs
du système complémentaire: l'inhibiteur du Cl (Cl-INH),
l'inactivateur du C3b (C3b-INA) et le /31H. Les concentrations
sériques de ces protéines, au moment de Ia biopsie, ont aussi été
mesurées. Afin d'étudier la modulation de l'activation du com-
plément par ces trois protéines de contrôle au cours de MGN et
MPGN, Ia relation entre la protéine de contrôle et la protéine
dont elle régule l'activité a été examinée de quatre facons: (a) la
concordance entre Ia presence de Ia protCine de contrôle et des
composes regulés a été recherchée, (b) les correlations entre
l'intensité des dépôts des protéines de contrôle et du corn-
plément ont été mesurées, (c) les modalités de distribution des
protéines a b'intérieur des glomérules ont été comparées, et (d)
les concentrations sénques des protCines de contrôle et des corn-
posants qu'elles régulent ont été examinées. Cl-INH (23
biopsies sur 35) et /31H (34 biopsies sur 36) étaient souvent dé-
poses dans les deux maladies. C3b-INA n'a été que rarement
observe dans MPGN (4 biopsies sur 19). Cela très probablement
car les deux premieres protéines modulent I'activation du corn-
plément de facon stechiometrique alors que C3b-INA agit de fa-
con enzymatique. Une relation a été démontrée C1-INH et Cis
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et entre f3lH et C3 dans les deux groupes abors qu'aucune rela-
tion n'a ëté observée entre C3b-INA et C3. Concluons. Ii n'y a
pas de deficit généralise dans Ia modulation de I'activation du
complement dans MGN ou MPGN.
Complement activation principally occurs by one
of two pathways. Immune complexes activate the
classical complement pathway by converting pre-
cursor Cl to CI [1]. CI has two natural substrates,
C4 and C2, which, when cleaved by Cl, in the pres-
ence of magnesium cations, form the classical path-
way C3 convertase C42 [2]. The action of Cl on C4
and C2 is modulated by Cl-inhibitor (CJ-INH),
which binds to the active esterolytic site on Cls [3].
The alternative pathway is probably undergoing
continuous "tick-over" [4], which is normally un-
der the control of two plasma proteins, C3b in-
activator (C3bINA) and /31H globulin. C3b-INA en-
zymatically inactivates C3b [5], and f3lH not only
potentiates the inactivation of C3b by C3bINA [6]
but also binds to C3b, blocking its ability to partici-
pate in both the classical and alternative pathways
[7]. In addition, f3lH displaces Bb from the
tive_pathway C3 converting enzymes C3bBb and
C3bBbP [8]. Amplification of the alternative path-
way "tick-over" results from the introduction of
complex bacterial or yeast polysaccharides, rabbit
erythrocytes [9—Il], cobra venom factor [12], or
nephritic factor [8] into serum. These agents all
have the common property of generating C3 con-
verting enzymes, which resist the modulatory influ-
ence of C3b-INA and /3IH. Amplification of normal
alternative pathway turnover also occurs when ei-
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ther regulatory protein is absent from the serum [4,
13, 14] or when excessive C3b is generated by acti-
vation of the classical pathway [15]. In this latter
case, relative reductions in the plasma concentra-
tions of C3b-INA and/or /31H may be important
[15—17].
Activation of the complement system leads to the
generation of phlogistic molecules [18], which may
be important in the pathogenesis of many types of
glomerulonephritis. Membranous glomerulonephri-
tis (MGN) characteristically involves the thickening
of capillary loops with little or no proliferation of
glomerular cells [19]. With the periodic acid-methe-
namine silver stain, the capillary wall thickening is
shown to be caused by an increase in basement
membrane, which may have an irregular appear-
ance. By electron microscopy, electron-dense de-
posits are found in a subepithelial position and may
be surrounded or partially surrounded by exten-
sions of the basement membrane.
Immunofluorescent studies in MGN suggest that
activation of complement is primarily by the classi-
cal pathway [20, 21]. There is little evidence from
measurement of serum levels of complement com-
ponents that activation is taking place in the circula-
tion, because concentrations of components are sel-
dom reduced [22, 23].
In membranoproliferative glomerulonephritis
(MPGN), thickening of capillary walls also occurs
and may give the appearance of a double basement
membrane. Associated with the basement mem-
brane changes, there is extensive proliferation of
mesangial cells and increase in matrix resulting, on
occasions, in a lobular appearance. By electron mi-
croscopy, two distinct types of MPGN may be rec-
ognized [24-26]. In the subendothelial type, elec-
tron-dense deposits occur mainly in a sub-
endothelial position, and the capillary wall
thickening is due mainly to the interposition of
mesangial cells and matrix between the basement
membrane and subendothelial cells. In the dense-
deposit variant of MPGN, the thickening of capil-
lary walls is due mainly to electron-dense material
found within the membrane itself. Some mesangial
interposition may also exist, and electron-dense de-
posits may be present in the mesangium.
In contrast to MGN, complement activation in
MPGN presents a more complex picture. In the
subendothelial type, there is evidence of activation
both of the alternative pathway and, to a lesser ex-
tent, the classical pathway based on reduced levels
of C3, factor B [27, 28], and sometimes Clq [27] in
the circulation, and glomerular deposition of Clq,
C3, and properdin [20, 21]. In dense-deposit dis-
ease, the type most frequently associated with pres-
ence of circulating C3 nephritic factor, alternative
pathway activation is most pronounced in the circu-
lation [27]. Immunofluorescent studies of renal
biopsies with the dense-deposit variant show intra-
glomerular deposition of C3 with no significant dep-
osition of properdin or Clq [26, 27].
We have attempted to define the possible role of
the regulatory proteins of the complement system in
the pathogenesis of MGN and MPGN by using im-
munofluorescence to examine the relationship of
the regulatory proteins to the proteins whose activi-
ty they regulate in the glomenili, and by measuring
the serum levels of these proteins.
Methods
Renal biopsy material. Percutaneous renal
biopsies were obtained from 41 patients, 22 with
MGN and 19 with MPGN. All patients in the MGN
group, at the time of biopsy, had proteinuria ranging
from 1 to 18.7 g per 24 hours (mean, 7.2 g). Serum
creatinine concentrations were all within normal
limits, ranging from 65 to 130 smoles/1iter (mean, 92
moles/liter). In the MPGN group, 2 patients had
no detectable proteinuria at the time of biopsy. In
the others, proteinuria ranged from 0.5 to 10 g per
24 hours (mean, 3.9 g). The range of serum creati-
nine in the MPGN group was 70 to 961 pmoles/liter
(mean, 301 smoles/liter), with nine values above
the normal range.
Diagnoses were based on light microscopy find-
ings following the staining of 2- corrosive-formol-
fixed paraffin-embedded sections with haematoxy-
lin and eosin, Masson, Martius scarlet blue, period-
ic acid Schiff, and periodic acid silver-methenamine
[29]. Two to 33 (mean, 14) glomeruli were available
for study in the MGN group, and 5 to 52 (mean, 19)
in the MPGN group. All biopsy samples were exam-
ined by a renal pathologist and categorized accord-
ing to the pathologic descriptions in the in-
troduction. In addition, diagnoses were confirmed
by electron microscopy in 11 MGN patients and 11
MPGN patients. Because electron microscopy re-
sults were not always available, MPGN biopsy sam-
ples were not subdivided into subendothelial type
and dense-deposit disease. Of the 11 MPGN biopsy
samples subjected to electron microscopic exami-
nation, one was a dense-deposit disease, and the re-
maining 10 had subendothelial deposits. The 8
biopsy samples not examined by electron micros-
copy all came from patients who were nephntic-fac-
tor negative at time of biopsy and therefore were
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more likely to be of the subendothelial type, be-
cause the dense-deposit variant is normally associ-
ated with the presence of nephritic factor [27].
Tissue samples for immunofluorescence were
embedded in Tissue Tek embedding medium
(Miles) immediately, snap-frozen in liquid nitrogen,
and stored in sealed containers at —70° C, until re-
quired. One to ten glomeruli (mean, 3.5) were avail-
able for study in the MGN biopsies, and 1 to 13
(mean, 5.5) in the MPGN group.
Human serum sa,nples. Serum samples were ob-
tained at time of biopsy from 11 MGN patients and
17 MPGN patients. These were aliquotted to mini-
mize freezing and thawing and stored at —70° C
until required. All samples were thawed in a 37°-C
water bath and then maintained at 0° C until refro-
zen at —70° C.
Antisera. Rabbit antisera to human Cls, fluores-
cein isothiocyanate (FITC)-conjugated rabbit anti-
goat immunoglobulin (Hoechst Pharmaceuticals),
rabbit anti-C3b-INA (Prof. P. J. Lachmann), and
goat antihuman CS (Dr. D. Schultze) were obtained
from the sources indicated.
Antisera to human Clq, C4, C1-INH, C3, proper-
din, factor B, and /31H were prepared in rabbits by
immunization of purified proteins in Freund's com-
plete adjuvant (FCA) (Difco). Antibody to rabbit
globulin was produced by immunization of a sheep
with rabbit globulin in FCA. This antibody was con-
jugated to FITC by a standard technique [30].
Clq [31], CIs [32], C4 [33], CI-INH [34], C3 [35],
CS [35], properdin [36], factor B [37], C3b-INA [14],
and /31H [6] were purified as described. Rabbit and
goat globulin were prepared by ammonium sulphate
precipitation.
All antigens, with the exception of rabbit and goat
globulin gave single precipitin lines against an anti-
serum to normal human serum. C4, C3, CS, factor
B, /31H, and C3b-INA gave single lines on elec-
trophoresis in sodium dodecyl sulphate poly-
acrylamide gels run under nonreducing conditions.
All antisera except sheep antirabbit globulin and
rabbit antigoat globulin were shown to be mono-
specific by double diffusion and immuno-
electrophoresis against normal human serum. Their
specificity was established by precipitation against
the relevant antigen preparation, which was homog-
eneous as ascertained above, and possessed the ex-
pected functional characteristics of the molecule.
Rabbit antigoat globulin and sheep antirabbit globu-
lin gave three precipitin lines against normal goat
and rabbit serum, respectively, and against the rele-
vant globulin preparation.
All antisera for immunofluorescence were titrated
against at least two positive biopsy samples, and the
dilution chosen was one that gave highest intensity
with minimum background staining. In all cases,
this was found to be at least two doubling dilutions
before the end point of staining.
Immunofluorescence. Immunofluorescent stain-
ing was carried out on 4- frozen sections as pre-
viously described [38]. Renal biopsy samples were
examined for the presence and distribution of C lq,
Cis, C4, Cl-INH, C3, CS, properdin, factor B,
C3b-INA, and $1H. All positive biopsy samples
were scored as 1 to 4 for intensity of staining: grade
1 = trace, grade 2 = weak, grade 3 = moderate,
grade 4 = intense.
Radial i,nmunod,ffusion. Serum concentrations
of Clq, Cls, C4, CI-INH, C3, CS, properdin, factor
B, C3b-INA, and /31H were estimated by radial im-
munodiffusion [39]. The concentrations of com-
ponents were calculated by reference to a standard
serum pool and were expressed in micrograms per
milliliter for all components, except C3b-INA,
which was calculated as a percentage of the pool.
Serum samples were obtained from SO normal
people, and the normal ranges were calculated by
using the mean level found for each component 2
SD from the mean. The normal range for each com-
ponent was: Clq, 283 to 627 g/ml; Cls, 24 to 49 Lg/
ml; C4, 149 to 550 pg/ml; Ci-INH, 121 to 303 g/ml;
C3, 769 to 1794 sgIml; CS, 84 to 170 sgIml; proper-
din, 13 to 41 g/ml; factor B, 111 to 303 pg/ml; fllH,
156 to 356 g/ml; C3b-INA, 55 to 123%.
C3 nephritic factor assay. The assay used was
based on the utilization of C3. Normal human
serum samples (150 sl) were incubated at 37° C for
20 mm with SO tl of test serum in the presence of
0.01 M EGTA with 0.OOS M magnesium chloride. A
control with 0.01 M EDTA was used. After in-
cubation, the reaction was stopped by the addition
of 100 pi of 0.1 M EDTA. The residual C3 was as-
sayed by a stoichiometric hemolytic titration [40]
with EAC14°'°'2 cells [41]. Three patients in the
MPGN group were found to be nephritic-factor-
positive.
Statistical analysis. Correlations between the in-
tensity of deposition of the various complement
components within the kidney were calculated by
the Spearman-Rank correlation test [42].
Because serum levels of complement com-
ponents in the disease groups were generally not
normally distributed, the probability that serum
concentrations differed significantly from normal
was assessed using the median test [42].
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Results
Frequency and intensity of glomerular deposition
of complement and control proteins. Table I shows
the number of biopsy samples positive for each
component in the disease groups and an index of the
intensity of deposition, based on the mean score of
the positive biopsy samples in each group. C3 was
found deposited in all but one of the 41 biopsy sam-
ples, and classical pathway activation was evident
in both MGN and MPGN with 77% and 74% of
biopsy samples, respectively, showing deposition
of at least one classical pathway component. Cl
subcomponents, however, were seen in only 40% of
the MGN biopsy samples and 32% of MPGN biopsy
samples. Of the alternative pathway components,
factor B was absent in MGN and was found in only
2 MPGN kidneys, and properdin was detected in
only 4 MGN biopsy samples but in 12 of 16 MPGN
biopsy samples, With the exception of Clq, all pro-
teins were found in greater concentrations in the
glomeruli of patients with MPGN. Of the proteins
that stoichiometrically modulate complement ac-
tivation, CI-INH and /31H were deposited in both
diseases. Ci-INH was found more frequently in
MGN than it was in MPGN. 13111 was found in all
but 2 MGN biopsy samples and all MPGN biopsy
samples including 3 from patients with nephritic
factor, one of whom had dense-deposit disease.
C3b-INA was never found in MGN but was present
in four cases of MPGN.
Concordance between deposition of con trot pro-
teins and related comple,nent components. In the
MGN group, C4 was found in association with Cl-
INH in 12 biopsy samples (Table 2). C4 was found
in the absence of Cl-INH in 2 biopsy samples, and
Ci-INH was found in the absence of C4 in 3 biopsy
samples. In contrast to the high degree of con-
cordance between Ci-INH and C4, there was little
relationship between Cls and Ci-INH. CI-INH
was found without Cis in 10 of 15 biopsy samples.
A far higher degree of concordance between dep-
osition of these components was found in the
Table 2. Concordance between regulators and complement
proteins with which they interacts
Present(+)
orabsent(—) MGN MPGN
Cls+C1-INH+ 5 6
Cis + Ci-INH — 1 3
Cis Ci-INH + 10 2
C3+C3bINA+ 0 4
C3 + C3bLNA — 19 15
C3—C3bINA + 0 0
C5+C3bINA + 0 2
CS + C3bINA — 18 8
C5—C3bINA+ 0 2
C3+131H+ 18 16
C3+/31H— 1 0
C3—f31H+ 0 0
C5+/31H+ 16 12
C5+j3lH— 2 0
C5—/31H+ 1 4
B+f3lH+ 0 2
B+1H— 0 0
B—/31H+ 18 14
C4 + Ci-INH ÷ 12 8
C4+Ci-INH— 2 2
C4—C1-INH+ 3 0
C4+C3bINA+ 0 4
C4 + C3bINA — 14 5
C4—C3bINA+ 0 4
P+C3bINA+ 0 3
P+C3bINA— 4 9
P—C3bINA+ 0 1
C4+/31H+ 12 10
C4+/31H— 2 0
C4—131H+
P+f311-{+ 4 12
P+f3lH— 0 0
P—/31H+ 14 4
MGN is membranous glomerulonephritis, and MPGN is
membranoproliferative glomerulonephritis.
MPGN group, and again the highest degree of asso-
ciation was between Ci-INH and C4.
The association between 13111 and C3b-INA and
the other proteins that interact with C3b is also
shown in Table 2. C3b-INA was not present in any
MGN biopsy samples, and in MPGN it was never
found in the absence of C3 or C4, although in 2
biopsy samples C3b-INA was found without CS dep-
osition. C3-INA and factor B were not found in the
Table 1. Glomerular deposition of complement components in membranous and membranoproliferative glomerulonephritis
Clq Cis C4 Ci-INH C3 CS P B C3bINA f3lH
+ tnt. + tnt. + tnt. + tnt. + mt. + mt. + tnt. + mt. + mt. + mt.
MembranousGN—l.8
Membrano- 1.4 — 2.0
19 15proliferative GN
!
-
17
1.5
1.7
15
8
15
1.6
2 1
1
-
.!!
19
1.8
2.4
!
19
!
15
2 .1
2.6
'
12
is.
2.0
0
--
1.3
0
.
1.9
18
17
T
1.8
25•
a Subheadings are defined as: + number of biopsy samples positive; tnt.. index of mtensity based on the mean score ofthe positive
biopsy samples in each group.
Control of complement activation 539
same biopsy samples. Of the 4 biopsy samples posi-
tive for C3b-INA, 3 had deposition of properdin.
f31H was found in 34 of 35 biopsy samples posi-
tive for C3 and was absent in the biopsy sample
where C3 was not deposited. f31H was sometimes
found without deposition of C5 and often without
factor B or properdin, particularly in MGN. Proper-
din and factor B were never found without f3lH, but
in 2 MGN biopsy samples C5 was found where
/31H-staining was negative.
Correlations between staining intensities of regu-
latory and other proteins. Using the scores for in-
tensity of staining for each component in each
biopsy, we examined the correlation in intensity of
deposition between the various complement com-
ponents and control proteins. Table 3 shows the
Spearman-Rank correlation coefficient (r) and prob-
ability value (P). The intensity of CT-INH deposi-
tion correlated with that of Cls and C4 in MPGN,
but in MGN no significant relationship was found.
Positive correlations between intensity of /31H and
C3, CS and properdin were found in both disease
groups. In view of the small number of biopsy sam-
ples positive for C3b-INA, correlation analyses
were not performed.
Distribution patterns of complement andregula-
tory proteins. The patterns of distribution of com-
plement proteins within each biopsy sample were
very similar. To establish the importance of the role
of regulatory proteins, we stained serial sections for
Cis and Cl-INH (Fig. 1) and C3 and /31H (Fig. 2); in
these situations, the control proteins and the pro-
teins that they regulate had almost identical distri-
bution patterns. C3b-INA was always found in a
focal and segmental pattern, but deposition of C3
was diffuse.
Serum concentrations of complement com-
ponents. The serum concentrations of complement
components and control proteins in membranous
and membranoproliferative glomerulonephritis pa-
tients are shown in Fig. 3.
Table 3. Correlations between control proteins and complement
proteins with which they interacta
MGN
P r
MPGN
P
Cl-INHIC1s 0.13 NS 0.43 <0.05
Ci-INH/C4 0.25 NS 0.79 <0.001
131H1C3 0.39 <0.05 0.53 <0.02
$1HIC4 0.28 NS 0.12 NS
f3lH/C5 0.52 <0.02 0.61 <0.01
/31H/P 0.39 <0.05 0.49 <0.05
r is the Spearman-Rank correlation coefficient.
In the MGN group, apart from one low value for
C3b-INA, all other values were within or above the
normal range, as were the means for each com-
ponent. With the median test, Clq, C4, Ci-INH,
C3, CS, and f3lH were all shown to be significantly
above the normal range.
In the MPGN group, C3 and factor B concentra-
tions were significantly lower than were normal
and isolated low values for each component ex-
cept Ci-INH. Cl-INH values as a group were sig-
nificantly above normal.
All 3 patients with nephritic factor had reduced
C3 concentrations. One also had a low properdin
concentration, and another had reduced concentra-
tions of factor B and the classical pathway com-
ponents Clq, Cls, and C4.
Discussion
In the study of the role of complement activation
in glomerulonephritis, it is difficult to establish
whether activation is occurring in the circulation,
within the kidney, or in both. In MGN, despite dep-
osition of complement components in renal biopsy
samples [20], circulating levels of these proteins
were normal [22, 23]. It is possible, therefore, that
activation is taking place entirely within the gb-
meruli. It is also possible, however, that increased
synthesis of components may mask the effects of hy-
percatabolism in the circulation. In MPGN, some
studies have presented evidence of severe activa-
tion of both pathways of complement activation
with reduced serum concentrations of C3, Clq, and
factor B [26—28]. But, in the glomeruli of patients
with the subendothelial type of MPGN, properdin is
often present [27], whereas Clq is seldom found
[26, 27]; in dense-deposit disease, components of
the classical and alternative pathways generally do
not accompany C3 deposition. In the dense-deposit
variant particularly, it is therefore possible that dep-
osition of C3 in the kidney is secondary to activa-
tion in the circulation. No evidence exists, how-
ever, to substantiate either of these possibilities in
MGN or MPGN. Nevertheless, the data we have
presented give an insight into the pathways of acti-
vation and the role of the regulatory proteins in
MGN and MPGN.
Pathways of complement activation. In MGN,
evidence for classical pathway activation was based
on the detection of Clq, Cls, and C4 in the glomeruli
(Table 1). That the alternative pathway was also ac-
tivated was suggested by the deposition of proper-
din in 4 of 20 MGN patients. Properdin was not
found in one published study of 4 MGN biopsy sam-
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Fig. 1. Pattern of deposition of C/s (on the left) and C/-INH (on the right) in the same giomerulus on adjacent sections from a MPGN
biopsy. (Final magnifIcation, ><400)
Fig. 2. Pattern of deposition of (3(on the left) and /3/H (on the right) in the same glomerulus on adjacent sections from a MPGN biopsy.
(Final magnification, x400)
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Fig. 3. Serum concentrations of complement components and con trot proteins in MGN and MPGN. The shaded area represents the
normal range, and the numbers at the bottom of each column are the probability values, indicating whether the values are high or low.
The results of the nephritic factor positive sera are shown as squares.
pies [21]. The deposition of C3 and C5 demonstrates
activation of the terminal sequence.
Reduced serum concentrations of classical or a!-
ternative pathway proteins were not found, which is
in agreement with other studies [23, 24]. In fact,
some elevated concentrations of all components
were found, and, in the case of Clq, C3, and C5,
these levels were significantly raised. Because these
proteins were deposited within the glomeruli, it is
probable that their catabolic rates were increased.
The MGN patients also had proteinuria, which
would also tend to reduce concentrations of certain
plasma proteins. It is therefore likely that the ele-
vated serum concentrations represent increased
synthesis.
In the MPGN group, deposition of Clq, Cls, and
C4 (Table 1) demonstrated that classical pathway
activation was taking place in most patients. Acti-
vation of the alternative pathway was suggested by
the frequent finding of properdin and the occasional
deposition of factor B. In the single diagnosed
dense-deposit biopsy sample, there was no appar-
ent deposition of properdin or factor B. This ab-
sence has been recorded by others [26, 27]. Detec-
tion of C3 and C5 again shows that the terminal se-
quence was activated in MPGN. Absence of factor
B in most biopsy samples in this study is not in-
compatible with alternative pathway activation be-
cause factor B decays from the alternative pathway
C3 and C5 convertases [43] and may also be dis-
placed by f31H [8]. It must also be emphasized that
deposition of properdin does not necessarily mean
that alternative pathway activation is occurring, as
properdin can bind to C3b alone [44] or to a C3b-
Ctq as C4 C1-INH c3 Cs P B CY,INA BIH
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/3lH complex [45, 46] in the absence of factor B and
therefore without generation of convertase activity.
Regulation of complement activation. In MGN,
Ci-INH was frequently deposited (Table 1), and the
patterns of deposition of Ci-INH and Cis were
very similar where both were deposited. There was,
however, no correlation between intensity of depo-
sition of Ci-INH and Cis (Table 3), and the con-
cordance between these proteins (Table 2) was also
poor, with Cis being found in only 5 of 15 biopsy
samples positive for Ci-INH. There are three pos-
sible explanations for this. (1) Ci-INH may mask
antigenic sites on the Ci-Cl-INH complex. Zic-
cardi and Cooper [47] have recently shown that this
may occur. (2) Ci-INH may be regulating some
plasma enzyme other than Cls [3],(3) The Cis anti-
serum may be less potent than Cl-INH antiserum.
We are unable to discriminate among these possi-
bilities.
In MPGN, evidence for a regulatory role for Ci-
INH was based on its presence (Table 1), the good
concordance between biopsy samples positive for
Cis and Ci-INH (Table 2), the significant correla-
tion between intensity of deposition of Cis and CT-
INH (TAble 3) and the close similarity in distribu-
tion patterns of Ci-INH and Cis (Fig. 1).
Because we have demonstrated some relation-
ship between Cls and Ci-INH in the glomeruli in
MGN and particularly MPGN, and because serum
levels of these components were either normal or
raised, it is unlikely that there is a generalized
breakdown in the intrinsic regulation of classical
pathway complement activation in MGN and
MPGN.
The biological activities of C3b involve its prop-
erties of binding with factor B, properdin, CS, and
C3b receptors and are regulated by at least two
plasma proteins, C3b-INA and /3lH [5-8].
C3b-INA was rarely found deposited in the kid-
ney, and thus concordance and correlation studies
could not be undertaken. The mean serum concen-
trations of C3b-INA were similar in both groups
(Fig. 3), and were within the normal range. Serum
C3b-INA concentrations were reduced in 3 patients
(1 with MGN and 2 with MPGN). The serum C3
concentrations in the 2 MPGN patients, with re-
duced levels of C3b-INA, were extremely low, and
the MGN patient with low C3b-INA levels was 1 of
the 4 patients in that group with glomerular deposi-
tion of properdin. Thus, in these 3 patients it is pos-
sible that increased complement activation may be
the result of a breakdown of C3b-INA-mediated
regulation.
Because of the enzymatic nature of the inter-
action of C3b-INA with C3b, the absence of C3b-
INA does not necessarily exclude the possibility
that regulation is taking place.
Good concordance between C3 and f31H deposi-
tion (Table 2), close similarities in their patterns of
distribution (Fig. 2), and the positive correlation be-
tween the intensities of deposition of C3 and /3lH in
both MGN and MPGN argue that /31H is modu-
lating complement activation in these diseases.
Observations compatible with this role are the
finding of CS in 2 biopsy samples not staining for
f31H and /3lH staining in 5 biopsy samples negative
for C5 (Table 2). In addition ,3lH was found in the
absence of properdin in 4 MPGN biopsy samples,
and in 14 MGN biopsy samples (Table 2). One could
argue that the absence of /3lH in these situations
facilitates interaction of C3b with properdin and CS,
and the presence of f31H may, in some cases, limit
C3b activity as shown by the absence of CS or pro-
perdin. Facts against this conclusion are the posi-
tive correlations between the intensities of deposi-
tion of /31H and C5. and /31H and properdin in both
MPGN and MGN. These findings may be explained
by assuming that CS, properdin, and f3lH have dif-
ferent binding sites on the C3b molecule, and that
binding of one protein does not inhibit the binding
of others. Indeed, Conrad et al [46] have shown
that, when properdin is bound to C3b, binding of
/3lH is increased, perhaps by stabilizing the C3b-
j3lH complex.
f31H was present in the 3 MPGN biopsy samples
from patients with nephritic factor despite the fact
that the nephritic-factor-stabilized C3 convertase is
known to be resistant to the actions off3lH [8]. Pos-
sible reasons for this apparent anomaly are that (I)
intraglomerular complement activation is independ-
ent of nephritic factor, (2) the CS convertase formed
from the nephritic-factor-stabilized C3 convertase is
subject to the normal f3lH regulatory actions, (3) C3
conversion via the classical pathway coexists with
nephritic-factor-induced activation. Nephritic fac-
tor is an immunoglobulin that binds to the C3 con-
vertase [48], and the interaction between nephritic
factor and the convertase may activate the classical
pathway [49], or(4) f3lH may bind to proteins other
than C3b. Further studies are required to discrimi-
nate among these possibilities.
Despite the frequent presence of f3lH and the
good association between deposition off3lH and C3
in the glomeruli, it is still possible that the local-
ization of /3lH in the kidney does not represent ef-
fective regulation of the activities of C3b by this
Control of complement activation 543
molecule. Two explanations for the presence of
/31H in the absence of regulation may be suggested.
It is known that sialic-acid-deficient surfaces offer a
"protected" site for C3b, preventing effective regu-
lation by /31H [50, 51], and basement membranes
isolated from glomerulonephritic kidneys have been
shown to contain only half the sialic acid content of
a normal basement membrane [52]. These mem-
branes may therefore protect" C3b, allowing am-
plification of the alternative pathway. Studies using
neuraminidase-treated sheep erythrocytes have
shown that in this protected" situation about 10%
of C3b may bind /3lH [53], and therefore, in the kid-
ney, the presence of/3lH may indicate that it is con-
trolling only a small percentage of the C3b mole-
cules with the remainder retaining their activity.
Although this possibility could not positively be
excluded, the similar relative intensities of C3 and
/31H in both MGN and MPGN (Table 1) may sug-
gest that, at most, only a small proportion of C3b
molecules are "protected" in this way. The second
possibility is that the anti-/31H antiserum may be
contaminated with antibodies to C4-binding protein
(c4-bp). Recently, Fujita, Gigli, and Nussenzweig
[54] showed that C4-bp binds to C4b and catalyzes
the degradation of C4b by C3b-INA. These authors
also showed that /31 H preparations were frequently
contaminated with C4-bp and that anti-$1H antisera
contained anti-C4-bp specificity. Thus some of the
f31H staining could have been due to C4-bp. Al-
though again we cannot exclude this possibility, the
/31H antigen used in the preparation of the anti-
serum gave a single line on sodium dodecyl sulphate
polyacrylamide gel electrophoresis and possessed
the characteristic properties of/31H [9], but did not
bind significantly to EAC4, potentiate the in-
activation of C4b by C3b-INA, or destabilize C42.
The effect of the /31 H preparation on cleavage of
C4b in solution was not studied. Immunization of
rabbits with this antigen gave an anti-/31H anti-
serum containing a minor contaminant, migrating in
the a region which was removed by immuno-
adsorption [6]. Thus, it is unlikely that our anti-/31H
antiserum has anti-C4-bp specificity. Further evi-
dence to support this comes from the observation
that the only biopsy sample in which we found C4
deposition in the absence of C3 did not stain for
/31H.
Thus, we have presented evidence for control of
complement activation in both MGN and MPGN
and that the control response parallels demand. Un-
less more subtle regulatory or deregulatory process-
es exist, it is unlikely that significant complement
activation in MPGN and MGN is the result of the
breakdown of these mechanisms.
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